MCID: PRG009
MIFTS: 50

Progressive Multifocal Leukoencephalopathy malady

Categories: Rare diseases, Infectious diseases, Neuronal diseases

Aliases & Classifications for Progressive Multifocal Leukoencephalopathy

About this section
Sources:
11Disease Ontology, 13DISEASES, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 49NINDS, 50Novoseek, 54Orphanet, 62SNOMED-CT, 68UMLS, 69UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Progressive Multifocal Leukoencephalopathy:

Name: Progressive Multifocal Leukoencephalopathy 11 48 49 54 13
Leukoencephalopathy, Progressive Multifocal 48 39 68
Pml 11 48 54
 
Leukoencephalopathy Progressive Multifocal 50
Progressive Multifocal Leukoencephalitis 54

Characteristics:

Orphanet epidemiological data:

54
progressive multifocal leukoencephalopathy:
Inheritance: Not applicable; Age of onset: All ages

Classifications:



External Ids:

Disease Ontology11 DOID:643
ICD1030 A81.2
ICD9CM32 046.3
MeSH39 D007968
NCIt45 C26815
SNOMED-CT62 22255007
Orphanet54 ORPHA217260
ICD10 via Orphanet31 A81.2
MESH via Orphanet40 D007968
UMLS via Orphanet69 C0023524

Summaries for Progressive Multifocal Leukoencephalopathy

About this section
NIH Rare Diseases:48 Progressive multifocal leukoencephalopathy (PML) is a neurological disorder that damages the myelin that covers and protects nerves in the white matter of the brain. It is caused by the JC virus (JCV). By age 10, most people have been infected with this virus, but it rarely causes symptoms unless the immune system becomes severely weakened. The disease occurs, rarely, in organ transplant patients; people undergoing chronic corticosteroid or immunosuppressive therapy; and individuals with cancer, such as Hodgkin’s disease, lymphoma, and sarcoidosis.  PML is most common among individuals with acquired immune deficiency syndrome (AIDS). Last updated: 4/1/2011

MalaCards based summary: Progressive Multifocal Leukoencephalopathy, also known as leukoencephalopathy, progressive multifocal, is related to systemic lupus erythematosus and leukemia, acute promyelocytic, somatic. An important gene associated with Progressive Multifocal Leukoencephalopathy is ITGA4 (Integrin Subunit Alpha 4), and among its related pathways are Immune response_MIF-mediated glucocorticoid regulation and Cytokines and Inflammatory Response. Affiliated tissues include brain, t cells and kidney, and related mouse phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and liver/biliary system.

Disease Ontology:11 A viral infectious disease that involves reactivation of JC polyomavirus in immune-compromised individuals which causes the loss of white matter (which is made up of myelin, a substance the surrounds and protects nerve fibers) in multiple areas of the brain. The symptoms include hemiparesis, aphasia, dysarthria, hemianopia, cognitive impairment and coma.

NINDS:49 Progressive multifocal leukoencephalopathy (PML) is a disease of the white matter of the brain, caused by a virus infection that targets cells that make myelin--the material that insulates nerve cells (neurons).

Wikipedia:71 Progressive multifocal leukoencephalopathy (PML) is a rare and usually fatal viral disease characterized... more...

Related Diseases for Progressive Multifocal Leukoencephalopathy

About this section

Diseases related to Progressive Multifocal Leukoencephalopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 184)
idRelated DiseaseScoreTop Affiliating Genes
1systemic lupus erythematosus29.5CD40LG, IL2, PDCD1, TNF
2leukemia, acute promyelocytic, somatic12.3
3acute promyelocytic leukemia pml/rara type12.1
4spastic paraplegia-paget disease of bone syndrome10.5ITGA4, TNF
5linitis plastica10.5IL2, TNF
6maligant granulosa cell tumor of ovary10.5IL2, TNF
7graft-versus-host disease, protection against10.5IL2, TNF
8addison's disease10.5IL2, TNF
9splenic manifestation of prolymphocytic leukemia10.5IL2, TNF
10night blindness10.4CD40LG, TNF
11ileocolitis10.4CD40LG, TNF
12lipodermatosclerosis10.4IL2, TNF
13scleral disease10.4CD40LG, TNF
14non-secretory myeloma10.4CD40LG, TNF
15potter's syndrome10.4IL2, TNF
16suppurative uveitis10.4CD40LG, TNF
17agammaglobulinemia, microcephaly, and severe dermatitis10.4CD40LG, IL2
18strawberry gallbladder10.4CD40LG, IL2
19lymphoma10.4
20phlyctenulosis10.4CD40LG, TNF
21japanese encephalitis10.4CD40LG, IL2
22bolivian hemorrhagic fever10.4IL2, TNF
23alkhurma hemorrhagic fever10.4CD40LG, TNF
24fetal erythroblastosis10.4CD40LG, TNF
25epididymis adenomatoid tumor10.4CD40LG, TNF
26loin pain hematuria syndrome10.3CD40LG, TNF
27gonococcal bursitis10.3CD40LG, STAT1
28leukostasis10.3CD40LG, TNF
29gait apraxia10.3CD40LG, TNF
30malignant histiocytosis10.3CD40LG, TNF
31variola major10.3CD40LG, MBP
32foodborne botulism10.3CD40LG, TNF
33sapho syndrome10.3CD40LG, MBP
34crest syndrome10.3CD40LG, TNF
35diabetic angiopathy10.3CD40LG, MBP
36leukemia10.3
37inner ear cancer10.3CD40LG, TNF
38isolated congenital breast hypoplasia/aplasia10.3MBP, TNF
39temporal arteritis10.3CD40LG, MBP
40labyrinthine bilateral reactive loss10.3CD40LG, TNF
41fibrous histiocytoma10.3CD40LG, TNF
42lupus erythematosus10.2
43pyoderma gangrenosum10.2HTR2A, IL2, TNF
44dentin dysplasia10.2CD40LG, TNF
45sweat gland cancer10.2CD40LG, MBP
46neurilemmoma10.2MBP, TNF
47spinal polio10.2CD40LG, IL2
48allergic hypersensitivity disease10.2CD40LG, TNF
49gingival disease10.2MBP, RPS27A
50brucella abortus brucellosis10.2CD40LG, IL2, TNF

Graphical network of the top 20 diseases related to Progressive Multifocal Leukoencephalopathy:



Diseases related to progressive multifocal leukoencephalopathy

Symptoms & Phenotypes for Progressive Multifocal Leukoencephalopathy

About this section

GenomeRNAi Phenotypes related to Progressive Multifocal Leukoencephalopathy according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00250-A-18.4CD40LG, IL2, PDCD1, STAT1, TNF

MGI Mouse Phenotypes related to Progressive Multifocal Leukoencephalopathy according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053708.8IL2, MECP2, PDCD1, STAT1, TNF
2MP:00053978.4CD40LG, IL2, ITGA4, MBP, PDCD1, STAT1
3MP:00053908.4CD40LG, HTR2A, MECP2, PDCD1, STAT1, TNF
4MP:00053798.1CD40LG, HTR2A, IL2, MECP2, PDCD1, STAT1
5MP:00053857.8CD40LG, IGHMBP2, IL2, ITGA4, MECP2, PDCD1
6MP:00053847.6CD40LG, IL2, ITGA4, MBP, MECP2, PDCD1
7MP:00053877.6CD40LG, IL2, ITGA4, MBP, MECP2, PDCD1
8MP:00107687.2CD40LG, IGHMBP2, IL2, ITGA4, MBP, MECP2

Drugs & Therapeutics for Progressive Multifocal Leukoencephalopathy

About this section

Drugs for Progressive Multifocal Leukoencephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 61)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Natalizumabapproved, investigationalPhase 497189261-10-7
Synonyms:
189261-10-7
Anti-VLA4
Anti-alpha4 integrin
 
D06886
Natalizumab
Natalizumab (INN)
Tysabri
Tysabri (TN)
2
Methylprednisoloneapproved, vet_approvedPhase 4115383-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
3
Prednisoloneapproved, vet_approvedPhase 4115350-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
 
MLS001304083
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
4
Interferon beta-1bapprovedPhase 482145155-23-3
Synonyms:
Betaseron
 
Fibroblast interferon
IFN-beta
Interferon beta precursor
5Immunosuppressive AgentsPhase 4, Phase 212770
6Adjuvants, ImmunologicPhase 42484
7Anti-Infective AgentsPhase 4, Phase 2, Phase 121402
8Antiviral AgentsPhase 4, Phase 29732
9Interferon-betaPhase 4280
10interferonsPhase 42137
11Gastrointestinal AgentsPhase 4, Phase 28109
12Prednisolone hemisuccinatePhase 41153
13Prednisolone phosphatePhase 41153
14Protective AgentsPhase 47190
15AntiemeticsPhase 43888
16Autonomic AgentsPhase 49774
17Prednisolone acetatePhase 41153
18Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 412767
19Hormone AntagonistsPhase 412778
20glucocorticoidsPhase 44920
21Fingolimod HydrochloridePhase 487
22Antineoplastic Agents, HormonalPhase 45407
23HormonesPhase 413979
24Methylprednisolone acetatePhase 41153
25Peripheral Nervous System AgentsPhase 422776
26Neuroprotective AgentsPhase 41672
27Anti-Inflammatory AgentsPhase 410355
28Methylprednisolone HemisuccinatePhase 41153
29
LenograstimapprovedPhase 21202135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
30
DidanosineapprovedPhase 215069655-05-650599
Synonyms:
149409-57-4
2',3'-Dideoxyinosine
2',3'-Dideoxyinosine & Granulocyte-macrophage colony-stimulating factor
2',3'-Dideoxyinosine & Interferon-.alpha.
2',3'-Dideoxyinosine & sCD4(soluble recombinant protein)
2',3'-Dideoxyinosine (AIDS Initiative)
2',3'-Dideoxyinosine (ddI)
2',3'-dideoxyinosine, DDI, NSC 612049, Didanosine
2'3'-DIDEOXYINOSINE
2,3-Dideoxyinosine
2,3-dideoxyinosine
2DI
3'-Azido-3'-deoxythymidine + 2',3'-Dideoxyinosine
69655-05-6
9-((2R,5S)-5-(Hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one
9-((2R,5S)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one
9-((2R,5S)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one
9-((2S,5R)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-ol
9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine
9-(2,3-Dideoxy-beta-D-ribofuranosyl)hypoxanthine
9-[(2R,5R)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]-1,9-DIHYDRO-6H-PURIN-6-ONE
9-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one
9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one
9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one
AC-12026
AC1L19ET
AC1L3OPK
BMY 40900
BMY-40900
BRN 3619529
Benzeneethanamine, 4-methoxy-3-(2-phenylethoxy)-N,N-dipropyl-, hydrochloride
Bio-0685
C06953
C083832
CCRIS 805
CHEBI:490877
CHEMBL1460
CID119381
CID50599
CPD000058576
D00296
D2I
D3066
DB00900
DB02392
DDI
DDI and rIFN.alpha.2
DIDEOXYINOSINE
DRG-0016
DS-4152 & ddI
DdIno
Didanosina
 
Didanosina [INN-Spanish]
Didanosine
Didanosine (JAN/USAN/INN)
Didanosine and Interferon-.alpha.-2
Didanosinum
Didanosinum [INN-Latin]
Dideoxyinosine
Dideoxyinosine (DDI)
FT-0082664
HMS2051J11
HMS2089N20
HSDB 6548
Hypoxanthine ddN
Inosine, 2',3'-dideoxy- & Recombinant Interferon-.alpha.-2
Intron A & Videx
KS-1049
LOA & ddI
Listera ovata agglutinin & 2',3'-Dideoxyinosine
MLS000759469
MLS001055350
MLS001424118
MLS002154216
MolPort-002-507-371
MolPort-002-885-819
N,N-Dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride
N,N-diethyl-2-(4-methoxy-3-phenethyloxyphenyl)ethanamine hydrochloride
NCGC00090691-01
NCGC00159514-02
NCGC00159514-03
NCGC00164280-01
NE 100
NE-100
NSC 612049
NSC-612049
NSC612049
PC-SOD+ddI
S1702_Selleck
SAM001246673
SMR000058576
Sulfated polysaccharide-peptidoglycan DS-4152 & 2',3'-Dideoxyinosine
UNII-K3GDH6OH08
Videx
Videx (TN)
Videx EC
Videx EC(TM)(slow-release capsules)
Videx(TM)
ZINC13597823
ddI & GM-CSF
ddI & IFN-.alpha.
ddI & sCD4(rsCD4)
ddI + d4T combination
ddIno
didanosine
31
ZalcitabineapprovedPhase 2477481-89-224066
Synonyms:
.beta.-D-2',3'-Dideoxycytidine
.beta.-D-2',3'-Dideoxycytidine & Granulocyte-macrophage colony-stimulating factor
.beta.-D-DDC
1-(2,3-Dideoxy-beta-D-ribofuranosyl)cytosine
16803P
2',3'-DIDEOXYCYTIDINE
2',3'-Dideoxycytidine
2',3'-Dideoxycytidine & Interferon.alpha.
2',3'-Dideoxycytidine & Nanoparticles (from human serum albumin or polyhexylcyanoacrylate)
2',3'-Dideoxycytidine & sCD4(soluble recombinant protein)
2,3-dideoxycytidine
3'-Azido-3'-deoxythymidine/2',3'-Dideoxycytidine
36775_FLUKA
4-amino-1-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one
4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one
5-25-14-00313 (Beilstein Handbook Reference)
7481-89-2
AC-824
AC1L2N6R
BPBio1_001378
BRN 0654956
BSPBio_001253
C07207
C9H13N3O3
CCRIS 692
CHEBI:10101
CHEMBL853
CID24066
CPD000058253
Cytidine, 2',3'-dideoxy- & Colony-stimulating factor
Cytidine, 2',3'-dideoxy- & Interferon.alpha.
D 5782
D00412
D3581
D5782_SIGMA
DB00943
DDC
DDC (DDC)
DDCYD
DS-4152 & ddC
Dideoxycytidine
EU-0100360
HIVID
HMS1548B19
HMS1571O15
HMS2051H18
HMS2090C12
HSDB 7156
Hivid (TN)
Hivid(TM)
 
Hivid, Dideoxycytidine, NSC 606170, Zalcitabine
Interferon AD + ddC
KS-1130
LS-1645
Lecithinized superoxide dismutase & .beta.-D-2',3'-Dideoxycytidine
Lopac0_000360
MLS000069636
MLS000759540
MLS001055363
MLS001424210
MolPort-002-885-873
NCGC00090705-01
NCGC00090705-02
NCGC00090705-03
NCGC00090705-05
NCGC00090705-06
NCGC00090705-07
NCGC00090705-10
NCGC00179242-01
NSC 606170
NSC-606170
NSC606170
PC-SOD & ddC
Prestwick0_001037
Prestwick1_001037
Prestwick2_001037
Prestwick3_001037
Ro 24-2027/000
Ro-24-2027/000
S1719_Selleck
SAM001246779
SMR000058253
SPBio_003104
SRI-7707
Sulfated polysaccharide-peptidoglycan DS-4152 & 2',3'-Dideoxycytidine
TimTec1_004969
UNII-6L3XT8CB3I
UPCMLD-DP115
UPCMLD-DP115:001
ZINC00039906
Zalcitabine (JAN/USP/INN)
Zalcitabine [USAN:INN:BAN]
Zalcitibine
bmse000712
ddC
ddC & GM-CSF
ddC & IFN.alpha.
ddC & Interferon.alpha.
ddC & NP (from PHCA or HSA)
ddC & sCD4
ddC (Antiviral)
ddCyd
zalcitabine
32
VedolizumabapprovedPhase 249943609-66-3
Synonyms:
 
Entyvio
33
Cytarabineapproved, investigationalPhase 21093147-94-46253
Synonyms:
(beta-D-Arabinofuranosyl)cytosine
(beta-D-arabinofuranosyl)cytosine
1-.beta.-D-arabinofuranosyl-cytosine
1-Arabinofuranosylcytosine
1-beta -D-Arabinofaranosylcytosine
1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta -D-Arabinofuranosylcytosine
1-beta-D-Arabinofaranosylcytosine
1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta-D-Arabinofuranosyl-Cytosine
1-beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside
1-beta-D-Arabinosyl-Cytosine
1-beta-D-Arabinosylcytosine
147-94-4
1beta -Arabinofuranasylcytosine
1beta -D-Arabinofuranosylcytosine
1beta -D-Arabinosylcytosine
1beta-Arabinofuranasylcytosine
1beta-D-Arabinofuranosylcytosine
1beta-D-Arabinosylcytosine
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl- [CAS]
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl
30399_FLUKA
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone
4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
69-74-9 (hydrochloride)
AC-1075
AC1L1M4F
AC1Q52OJ
AI3-52329
AR3
Alexan
Ara-C
Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine
Ara-Cytidine
AraC
Arabinocytidine
Arabinofuranosyl Cytidine
Arabinofuranosylcytosine
Arabinosyl Cytosine
Arabinosylcytosine
Arabitin
Aracytidine
Aracytin
Aracytine
Arafcyt
BIDD:GT0371
BIDD:PXR0139
BTB15125
Beta-cytosine arabinoside
C02961
C1768_SIGMA
C2035
C9H13N3O5
CCRIS 913
CHEBI:28680
CHEMBL803
CHX 3311
CID6253
CPD000449317
CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9)
Citarabina
Citarabina [INN-Spanish]
Cytarabin
Cytarabina
Cytarabine
Cytarabine (JP15/USP/INN)
 
Cytarabine [USAN:INN:BAN:JAN]
Cytarabine liposome injection
Cytarabinoside
Cytarabinum
Cytarabinum [INN-Latin]
Cytarbel
Cytonal
Cytosar
Cytosar-U
Cytosine 1-beta-D-arabinofuranoside
Cytosine arabinofuranoside
Cytosine arabinose
Cytosine arabinoside
Cytosine arabinoside (VAN)
Cytosine beta-D-arabinofuranoside
Cytosine beta-D-arabinofuranoside hydrochloride
Cytosine beta-D-arabinoside
Cytosine, beta -D-arabinoside
Cytosine, beta-D-arabinoside
Cytosine-1-beta-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside hydrochloride
Cytosine-beta -D-arabinofuranoside
Cytosine-beta -arabinoside
Cytosine-beta-D-arabinofuranoside
Cytosine-beta-arabinoside
Cytosinearabinoside
D00168
DB00987
DepoCyte
Depocyt
Depocyt (TN)
Depocyt (liposomal)
Depocyte
EINECS 205-705-9
Erpalfa
FT-0082880
HMS2051K19
HMS2090A18
HSDB 3049
Intrathecal (injected into the spinal fluid) DepoCyt
Intrathecal cytarabine (also known as ara-C)
Iretin
LS-860
Lopac0_000316
MLS000758310
MLS001066340
MolPort-001-792-509
NCGC00093356-03
NCGC00093356-04
NCGC00093356-05
NCI-C04728
NSC 287459
NSC287459
S1648_Selleck
SAM001247012
SMR000449317
SR-01000075773-3
Spongocytidine
TL8001048
Tarabine
U 19920A
U-19,920
U-19920
UNII-04079A1RDZ
Udicil
ZINC03795098
beta -D-arabinosylcytosine
beta -arabinosylcytosine
beta -cytosine arabinoside
beta-Ara C
beta-Ara c
beta-Arabinosylcytosine
beta-Cytosine arabinoside
beta-D-Arabinosylcytosine
cytarabine
cytarabine liposome injection
cytosine-β-D-arabinofuranoside
34
Topotecanapproved, investigationalPhase 2339119413-54-6, 123948-87-860700
Synonyms:
(4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione
(S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
123948-87-8
9-Dimethylaminomethyl-10-hydroxycamptothecin
9-[(dimethylamino)Methyl]-10-hydroxy-(4S)-camptothecin
AC-11592
AC1L1TQZ
AC1Q6APZ
BSPBio_002348
C11158
C23H23N3O5
CCRIS 8163
CHEBI:107501
CHEBI:46035
CHEMBL84
CID60700
D08618
DB01030
HMS2090B20
HSCI1_000228
Hycamptamine
Hycamptin
Hycamtamine
Hycamtin
Hycamtin (TN)
LS-127395
 
MLS000759456
NCGC00178695-01
NCI60_004771
NCIStruc1_001659
NCIStruc2_001796
NChemBio.2007.10-comp24
NSC609699
SK&F-104864-A
SKF 104864
SKF-104864-A
SKF-S 104864
SMP2_000312
SMP2_000327
SMR000466344
TOPO
TOPOTECAN, HYCAMTIN
TPT
TTC
Topotecan (BAN)
Topotecan Hcl
Topotecan Hydrochloride
Topotecan Lactone
Topotecan Monohydrochloride, (S)-Isomer
Topotecan [INN:BAN]
Topotecan lactone
Topotecane
Topotecane [INN-French]
Topotecanum
Topotecanum [INN-Latin]
UNII-7M7YKX2N15
topotecan
35
ZidovudineapprovedPhase 249430516-87-135370
Synonyms:
-Azido-3&prime
-deoxythymidine
1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)thymine
3&prime
3' Azido 2',3' Dideoxythymidine
3' Azido 3' deoxythymidine
3'-Azido-2',3'-Dideoxythymidine
3'-Azido-3'-deoxythymidine
3'-Azido-3'-deoxythymidine & Concanavalin A
3'-Azido-3'-deoxythymidine & Erythropoietin
3'-Azido-3'-deoxythymidine & Heteropolyoxotungstate PM-19
3'-Azido-3'-deoxythymidine & Interleukin-1
3'-Azido-3'-deoxythymidine & Interleukin-2
3'-Azido-3'-deoxythymidine & Interleukin-6
3'-Azido-3'-deoxythymidine & Lithium & Erythropoietin
3'-Azido-3'-deoxythymidine & Lithium & Interleukin-1
3'-Azido-3'-deoxythymidine & Lithium & Interleukin-6
3'-Azido-3'-deoxythymidine & Lymphoblastoid Interferon
3'-Azido-3'-deoxythymidine & Sho-Saiko-To
3'-Azido-3'-deoxythymidine (AIDS)
3'-Azido-3'deoxythymidine & Interferon .alpha.
3'-Azidothymidine
3'-Deoxy-3'-azidothymidine
3'-azido-3'-deoxythymidine, AZT
3-Azido-3-deoxythymidine
30516-87-1
399024-19-2
A2169_SIGMA
AC1L1TKL
AC1Q2OEK
AZT
AZT & CD4(178)-PE 40
AZT & Colony-stimulating factor 2
AZT & Concanavalin A (ConA)
AZT & EPO
AZT & GM-CSF
AZT & HPA
AZT & IFN.alpha.
AZT & IL-1
AZT & IL-2
AZT & IL-6
AZT & Interferon-.alpha.-2
AZT & Li & EPO
AZT & Li & GM-CSF
AZT & Li & IL-1
AZT & Li & IL-6
AZT & Lymphoblastoid Interferon
AZT & NP (from PHCA or HSA)
AZT & PM-19
AZT & SST
AZT & rIFN.alpha.2
AZT & rsCD4 & rIFN.alpha.A
AZT & rsT4
AZT & sCD4
AZT & srCD4
AZT (Antiviral)
AZT Antiviral
AZT TRANSPLACENTAL CARCINOGENESIS STUDY
AZT+PRO 140
AZT, Antiviral
Antiviral AZT
Apo-Zidovudine
Azidothymidine
Aztec
BB_NC-1012
BPBio1_000403
BRD-K72903603-001-04-6
BSPBio_000365
BSPBio_003153
BW A509U
BW-A 509U
BW-A-509U
BW-A509U
BWA 509U
BWA-509U
BWA509U
C07210
CCRIS 105
CHEBI:10110
CHEBI:127307
CHEMBL129
CID35370
 
CPD000058351
Compound S
Cpd S
D00413
D015215
DB00495
DRG-0004
DS-4152 & AZT
DivK1c_000524
HMS1921J20
HMS2090G11
HMS2092D06
HMS501K06
HSDB 6515
IDI1_000524
Interferon AD + 3'-azido-3'-deoxythymidine
Intron A & AZT
K7 [P Ti2 W10 O40]
KBio1_000524
KBio2_001828
KBio2_004396
KBio2_006964
KBio3_002653
KBioGR_000703
KBioSS_001828
LS-1159
Liposomal AZT-SN-1
Liposomal AZT-SN-3
MLS000028548
MLS001055351
MLS001076358
MLS002153202
MLS002222249
Met-SDF-1.beta. & AZT
Met-SDF-1.beta. & Zidovudine
MolPort-002-507-286
NCGC00023945-03
NCGC00023945-04
NCGC00023945-05
NCGC00023945-08
NCGC00178237-01
NCGC00178237-02
NINDS_000524
NSC 602670
Novo-Azt
PC-SOD+AZT
Prestwick3_000333
Propolis+AZT
Racemic Liposomal AZT
Retrovir
Retrovir (TN)
Retrovir(TM)
SAM002548971
SMR000058351
SN-1-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
SN-3-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
SPBio_000834
SPECTRUM1502109
STK801891
Spectrum2_000927
Spectrum3_001507
Spectrum4_000332
Spectrum5_001101
Spectrum_001348
UNII-4B9XT59T7S
ZDV
ZIDOVUDINE [AZT]
ZINC03779042
ZVD
Zidovudin
Zidovudina
Zidovudina [Spanish]
Zidovudine (JAN/USP/INN)
Zidovudine EP III
Zidovudine [USAN:INN:BAN:JAN]
Zidovudine+PRO 140
Zidovudinum
Zidovudinum [Latin]
antiviral
azidodeoxythymidine
rIFN-beta seron & AZT
racemic-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
zidovudin
zidovudine
36
Emtricitabineapproved, investigationalPhase 2439143491-57-060877
Synonyms:
(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-.beta.-L-FTC
(-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(-)-2'-Deoxy-5-fluoro-3'-thiacytidine
(-)-FTC
(-)-beta-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine
(-)-cis-4-amino-5-Fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
(-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
(2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
(2R-cis)-4-amino-5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
.beta.-L-(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
1-(2-(Hydroxymethyl)oxathiolan-5-yl)-5-fluorocytosine
143491-54-7
143491-57-0
145213-48-5
2',3',5-FTC
2',3'-Dideoxy-5-fluoro-3'-thiacytidine
2'-Deoxy-5-fluoro-3'-oxa-4'-thiocytidine
2'-Deoxy-5-fluoro-3'-thiacytidine
2-FTC
3'-Thia-2'.3'-dideoxy-5-fluorocytidine
4-Amino-5-fluoro-1-((2R,5S)-2-hydroxymethyl-[1,3]oxathiolan-5-yl)-1H-pyrimidin-2-one
4-Amino-5-fluoro-1-[(2R,5S)-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone
4-amino-5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one
4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one
4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)[1,3]oxathiolan-5-yl]cytosine
524W91
AC1L1U3I
AC1Q4KUB
BW 1592
 
BW 524W91
BW-524W91
BW524W91
C122114
C12599
C8H10FN3O3S
CHEBI:31536
CHEMBL885
CID60877
Coviracil
Coviracil(TM)
D01199
DB00879
DRG-0208
Emtricitabin
Emtricitabina
Emtricitabine
Emtricitabine (JAN/USAN/INN)
Emtricitabinum
Emtriva
Emtriva (TN)
Emtriva(TM)
FT-0080009
HMS2089I05
HSDB 7337
LS-135838
LS-173184
NCGC00164564-01
RCV
Racivir
SBB066061
TL8000958
UNII-G70B4ETF4S
ZINC03629271
beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine
dOTFC
emtricitabine
37
Enfuvirtideapproved, investigationalPhase 258159519-65-016130199
Synonyms:
262434-79-7
C105196
DP178
Dp 178
Enfuvirtide
Enfuvirtide [USAN]
Envelope polyprotein GP160 precursor [Contains: Exterior membrane glycoprotein,GP120, Transmembrane glycoprotein,GP41]
Fuzeon
HSDB 7341
 
LS-183961
N-Acetyl-L-tyrosyl-L-threonyl-L-seryl-L-leucyl-L-isoleucyl-L-histadyl-L-seryl-L-leucyl-L-isoleucyl-L-alpha-glutamyl-L-alpha-glutamyl-L-seryl-L-glutaminyl-L-asparaginyl-L-glutaminyl-L-glutaminyl-L-alpha-glutamyl-L-lysyl-L-asparaginyl-L-alpha-glutamyl-L-glutaminyl-L-alpha-glutamyl-L-leucyl-L-leucyl-L-alpha-glutamyl-L-leucyl-L-alpha-aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-tryptophyl-L-asparaginyl-L-tryptophyl-L-phenylalaninamide
Pentafuside
Roche brand of pentafuside
T 20
T 20 (peptide)
T-20
T-20 cpd
T20 peptide
UNII-19OWO1T3ZE
peptide T20
38
Tenofovirapproved, investigationalPhase 2733147127-20-6464205
Synonyms:
(R)-9-(2-Phosphonomethoxypropyl)adenine
(R)-9-(2-Phosphonylmethoxypropyl)adenine
(R)-9-(2-phosphonomethoxypropyl)adenine
(R)-PMPA
147127-20-6
206184-49-8
AC-760
AC1LA9BO
Anh. tenofovir
Anhydrous tenofovir
Apropovir
CHEBI:45809
CHEMBL483
CID464205
D,L-Tenofovir
DB00300
GNA & Tenofovir
GS 1275
GS 1278
GS1278
 
HHA & Tenofovir
KS-5021
MolPort-003-850-411
NCGC00167535-01
PMPA
PMPA-(R)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Galanthus nivalis agglutinin (GNA)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Hippeastrum hybrid agglutinin( HHA)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- (9CI)
Phosphonic acid, [[2-(6-amino-9H-purin-9
S1401_Selleck
TDF
TFV
Tenefovir
Tenofovir
Tenofovir (anh.)
Tenofovir disoproxil
Tenofovir disoproxil fumarate
UNII-99YXE507IL
Viread
Viread, Tenofovir
[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid
39
MefloquineapprovedPhase 1, Phase 25653230-10-74046
Synonyms:
(+)-(11R,2'S)-erythro-Mefloquine
(+)-Mefloquine
(+)-Threo-Mefloquine
(-)-(11S,2'R)-erythro-Mefloquine
(-)-Mefloquine
(-)-Threo-Mefloquine
(DL-erythro-alpha-2-Piperidyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol
(R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol
(R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol
(S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol
(S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol
(S)-[2,8-bis(trifluoromethyl)quinolin-4-yl][(2R)-piperidin-2-yl]methanol
49752-90-1
51688-68-7
51742-87-1
51744-84-4
51744-85-5
53230-10-7
68682-27-9
AB00052310
AC1L1HAJ
AC1L249S
AC1L9UO6
AC1MHD7J
AC1MHD7O
AC1Q4K1I
AR-1G4597
BIDD:GT0596
BIDD:PXR0166
BPBio1_000190
BRD-A89585551-003-03-4
BSPBio_000172
C07633
C17H16F6N2O
CAS-51773-92-3
CHEBI:151162
CHEBI:403542
CHEMBL411329
CHEMBL411685
CHEMBL411686
CHEMBL416956
CID3000506
CID3000516
CID4046
CID40692
CID456309
D04895
DB00358
DivK1c_000790
EINECS 256-468-3
Erthro-.alpha.-[2-piperidyl]-2,8-bis[trifluoromethyl]-4-quinolinemethanol
HMS1922C09
HMS502H12
HSDB 6853
IDI1_000790
KBio1_000790
KBio2_001792
KBio2_004360
KBio2_006928
KBio3_002046
KBioGR_001392
KBioSS_001792
LS-142023
 
LS-187797
Lariam
Lariam (Hydrochloride)
MQ
Mefloquin
Mefloquina
Mefloquina [INN-Spanish]
Mefloquine
Mefloquine (USAN/INN)
Mefloquine HCL
Mefloquine [USAN:INN:BAN]
Mefloquine aziridine
Mefloquinone
Mefloquinum
Mefloquinum [INN-Latin]
Mephloquine
MolPort-003-981-155
Méfloquine
NCGC00016864-01
NCGC00094994-01
NCGC00094994-02
NCGC00094994-03
NCGC00094994-04
NCGC00161831-01
NCGC00161831-02
NINDS_000790
NSC157387
Prestwick0_000126
Prestwick1_000126
Prestwick2_000126
Prestwick3_000126
RO 13-7224
RO 13-7225
RTI1169-1-1
RTI1172-1-1
RTI1173-1-1
RTI1174-1-1
RTI1188-1-1
RTI1189-1-1
Racemic mefloquine
Ro 21-5998
Ro 21-5998 (Hydrochloride)
Ro 215998
Ro-21-5998-001
SPB-80406
SPBio_001591
SPBio_002111
SPECTRUM1503070
Spectrum2_001516
Spectrum3_000953
Spectrum4_001066
Spectrum5_001122
Spectrum_001312
UNII-TML814419R
WR 142490
WR-142,490
WR-142490
WR-177,602
[(R*,S*)-2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol
[2,8-bis(trifluoromethyl)quinolin-4-yl]-piperidin-2-ylmethanol
alpha-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol
alpha-2-Piperidyl-2,8-bis(trifluoromethyl)quinoline-4-methanol
mefloquine
nchembio.215-comp3
nchembio.87-comp20
40Anti-HIV AgentsPhase 23100
41Antimetabolites, AntineoplasticPhase 27171
42Anti-Retroviral AgentsPhase 23232
43ImmunoglobulinsPhase 26045
44topoisomerase I inhibitorsPhase 21328
45AntimetabolitesPhase 211774
46Reverse Transcriptase InhibitorsPhase 21880
47Nucleic Acid Synthesis InhibitorsPhase 24855
48AntibodiesPhase 26045
49Topoisomerase InhibitorsPhase 24945
50Antibodies, MonoclonalPhase 23795

Interventional clinical trials:

(show all 26)
idNameStatusNCT IDPhase
1Methylprednisolone During the Switch Between Natalizumab and FingolimodRecruitingNCT02769689Phase 4
2Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple SclerosisRecruitingNCT01981161Phase 4
3Safety and Effectiveness of Switching Relapsing MS Patients Treated With Natalizumab at Risk for PML to TeriflunomideActive, not recruitingNCT01970410Phase 4
4Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)TerminatedNCT01211665Phase 4
5Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple SclerosisTerminatedNCT01701856Phase 4
6Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)CompletedNCT00120367Phase 2
7Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected PatientsCompletedNCT00001048Phase 2
8Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML)CompletedNCT00002395Phase 2
9Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's DiseaseCompletedNCT00619489Phase 2
10Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)TerminatedNCT00746941Phase 1, Phase 2
11Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403TerminatedNCT00655824Phase 2
12Drug Exposure Registry for GSK2248761, an Investigational NNRTIUnknown statusNCT01458132
13A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 InfectionCompletedNCT00002270
14A Study to Evaluate the Use of Cidofovir (an Experimental Drug) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in AIDS PatientsCompletedNCT00000945
15Retrospective Study of the Survival of Patients Suffering From Hiv-related Progressive Multifocal LeukoencephalopathyCompletedNCT02895581
16Genetics of Progressive Multifocal Leukoencephalopathy and Acquired Immunodeficiency SyndromeCompletedNCT00342602
17JC Virus Reactivation in Multiple SclerosisCompletedNCT02004444
18A Study of ddI in Patients With AIDS Who Become Sicker While Taking ZidovudineCompletedNCT00002274
19JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With NatalizumabCompletedNCT01070836
20Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis of a Tysabri Patient CohortCompletedNCT01070719
21Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active ControlCompletedNCT01626248
22Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)RecruitingNCT01730131
23Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-CellsRecruitingNCT02694783Early Phase 1
24Evaluating Nulojix (Belatacept) Long-Term Safety in TransplantRecruitingNCT01386359
25Role of Inflammation in Progressive Multifocal Leukoencephalopathy (PML)Enrolling by invitationNCT01132053
26Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal LeukoencephalopathyTerminatedNCT01211639

Search NIH Clinical Center for Progressive Multifocal Leukoencephalopathy


Cochrane evidence based reviews: leukoencephalopathy, progressive multifocal

Genetic Tests for Progressive Multifocal Leukoencephalopathy

About this section

Anatomical Context for Progressive Multifocal Leukoencephalopathy

About this section

MalaCards organs/tissues related to Progressive Multifocal Leukoencephalopathy:

36
Brain, T cells, Kidney, Liver, Lung, Testes, B cells

Publications for Progressive Multifocal Leukoencephalopathy

About this section

Articles related to Progressive Multifocal Leukoencephalopathy:

(show top 50)    (show all 635)
idTitleAuthorsYear
1
Deep-Sequence Identification and Role in Virus Replication of a JC Virus Quasispecies in Patients with Progressive Multifocal Leukoencephalopathy. (27795410)
2017
2
The Risk of Progressive Multifocal Leukoencephalopathy in the Biologic Era: Prevention and Management. (27890176)
2017
3
Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod. (27994897)
2016
4
Progressive multifocal leukoencephalopathy secondary to rituximab-induced immunosuppression and the presence of John Cunningham virus: a case report and literature review. (27594961)
2016
5
Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs. (27696299)
2016
6
Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression. (27273076)
2016
7
Cidofovir for treatment of progressive multifocal leukoencephalopathy in a newly diagnosed sarcoidosis patient - a valid therapeutic option? (26944175)
2016
8
Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases. (27401179)
2016
9
Assessing understanding: Patients prescribed natalizumab for multiple sclerosis individual risk and symptoms of progressive multifocal leukoencephalopathy. (27862809)
2016
10
Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia. (27456945)
2016
11
Low-signal-intensity rim on susceptibility-weighted imaging is not a specific finding to progressive multifocal leukoencephalopathy. (26944139)
2016
12
Progressive multifocal leukoencephalopathy in an immunocompetent patient. (27042682)
2016
13
Rituximab-Associated Inflammatory Progressive Multifocal Leukoencephalopathy. (27965904)
2016
14
Progressive Multifocal Leukoencephalopathy in Primary Immune Deficiencies: Stat1 Gain of Function and Review of the Literature. (26743090)
2016
15
Progressive Multifocal Leukoencephalopathy with Balanced CD4/CD8 T-Cell Infiltration and Good Response to Mefloquine Treatment. (27301518)
2016
16
Progressive Multifocal Leukoencephalopathy in a Lung Transplant Recipient: Isolation of John Cunningham (JC) Virus from Bronchoalveolar Lavage. (27013844)
2016
17
Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review. (26743322)
2016
18
Progressive multifocal leukoencephalopathy in a patient with silicosis. (27416854)
2016
19
Expression of Signaling Molecules in Progressive Multifocal Leukoencephalopathy. (26531763)
2016
20
Neuropathology of JC virus infection in progressive multifocal leukoencephalopathy in remission. (26870672)
2016
21
Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry. (27997580)
2016
22
Drug-induced progressive multifocal leukoencephalopathy: a case/noncase study in the French pharmacovigilance database. (27736027)
2016
23
Treatment of Progressive Multifocal Leukoencephalopathy With Mirtazapine. (27401779)
2016
24
CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. (27815407)
2016
25
Differences in T cell cytotoxicity and cell death mechanisms between progressive multifocal leukoencephalopathy, herpes simplex virus encephalitis and cytomegalovirus encephalitis. (27817117)
2016
26
Rehabilitation outcome of progressive multifocal leukoencephalopathy in HIV-positive patients: a report of two cases. (27539012)
2016
27
Rituximab versus fingolimod after natalizumab in multiple sclerosis: Also consider progressive multifocal leukoencephalopathy risk. (27554031)
2016
28
Poster 346 Rehabilitation of Progressive Multifocal Leukoencephalopathy: A Case Report. (27673097)
2016
29
Progressive Multifocal Leukoencephalopathy in a HIV Negative, Immunocompetent Patient. (27529042)
2016
30
A case of progressive multifocal leukoencephalopathy with Takayasu arteritis and indolent adult T-cell lymphoma/leukemia. (26797479)
2016
31
Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy. (27600113)
2016
32
Primary cerebellar progressive multifocal leukoencephalopathy (PML) shows increased accumulation in (123)I-IMP SPECT. (26810523)
2016
33
Progressive multifocal leukoencephalopathy associated with infliximab. (27959350)
2016
34
Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature. (27134676)
2016
35
Single-molecule sequencing reveals the presence of distinct JC polyomavirus populations in patients with progressive multifocal leukoencephalopathy. (27571907)
2016
36
Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy. (27456891)
2016
37
JC Polyomavirus Abundance and Distribution in Progressive Multifocal Leukoencephalopathy (PML) Brain Tissue Implicates Myelin Sheath in Intracerebral Dissemination of Infection. (27191595)
2016
38
Sequential Onset of Varicella-Zoster Virus Encephalomeningitis and Progressive Multifocal Leukoencephalopathy in an Allogeneic Hematopoietic Stem Cell Transplant Recipient. (27938314)
2016
39
A case of progressive multifocal leukoencephalopathy with chronic renal failure, whose JC virus in cerebrospinal fluid disappeared after mefloquine-mirtazapine dual therapy. (27645758)
2016
40
Diagnostic delay in progressive multifocal leukoencephalopathy. (27231708)
2016
41
Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system. (27268272)
2016
42
Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks. (28039520)
2016
43
Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals. (27686675)
2016
44
Possible pitfalls in the diagnostic of progressive multifocal leukoencephalopathy. (26754416)
2016
45
Natalizumab-Related Progressive Multifocal Leukoencephalopathy-Immune Reconstitution Inflammatory Syndrome: A Case Report Highlighting Clinical and MRI Features. (27904430)
2016
46
Recurrence of progressive multifocal leukoencephalopathy despite immune recovery in two HIV seropositive individuals. (26727910)
2016
47
Progressive Multifocal Leukoencephalopathy and Systemic Lupus Erythematosus: Focus on Etiology. (27065427)
2016
48
Clearance of cerebrospinal fluid JCV DNA with mirtazapine in a patient with progressive multifocal leukoencephalopathy and sarcoidosis. (26857363)
2016
49
Progressive multifocal leukoencephalopathy after autologous peripheral blood stem cell transplantation in a patient with multiple myeloma treated with combination therapy. (27538654)
2016
50
Progressive multifocal leukoencephalopathy with bilateral middle cerebellar peduncle lesions confirmed by repeated CSF-JC virus tests and coexistence of JC virus granule cell neuronopathy. Report of a case. (27356732)
2016

Variations for Progressive Multifocal Leukoencephalopathy

About this section

Expression for genes affiliated with Progressive Multifocal Leukoencephalopathy

About this section
Search GEO for disease gene expression data for Progressive Multifocal Leukoencephalopathy.

Pathways for genes affiliated with Progressive Multifocal Leukoencephalopathy

About this section

Pathways related to Progressive Multifocal Leukoencephalopathy according to GeneCards Suite gene sharing:

(show all 18)
idSuper pathwaysScoreTop Affiliating Genes
19.8IL2, TNF
29.8IL2, TNF
39.7CD40LG, IL2
49.5IL2, ITGA4, TNF
5
Show member pathways
9.4CD40LG, IL2, TNF
69.4CD40LG, IL2, TNF
7
Show member pathways
9.4IL2, ITGA4, STAT1
8
Show member pathways
9.3IL2, STAT1, TNF
9
Show member pathways
9.3IL2, STAT1, TNF
109.3CD40LG, ITGA4, PDCD1
119.3IL2, MBP, TNF
12
Show member pathways
9.1RPS27A, STAT1, TNF
139.0HTR2A, MECP2, TNF
14
Show member pathways
9.0CD40LG, ITGA4, STAT1, TNF
158.9CD40LG, ITGA4, PDCD1, TNF
16
Show member pathways
8.8CD40LG, IL2, PDCD1, TNF
17
Show member pathways
8.6CD40LG, IL2, ITGA4, STAT1, TNF
188.4CD40LG, IL2, PDCD1, STAT1, TNF

GO Terms for genes affiliated with Progressive Multifocal Leukoencephalopathy

About this section

Biological processes related to Progressive Multifocal Leukoencephalopathy according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1leukocyte tethering or rollingGO:005090110.6ITGA4, TNF
2leukocyte cell-cell adhesionGO:000715910.5CD40LG, ITGA4
3cellular response to cytokine stimulusGO:007134510.5ITGA4, STAT1
4regulation of immunoglobulin secretionGO:005102310.3CD40LG, TNF
5regulation of tumor necrosis factor-mediated signaling pathwayGO:001080310.1RPS27A, TNF
6positive regulation of NF-kappaB transcription factor activityGO:00510929.7CD40LG, RPS27A, TNF
7negative regulation of apoptotic processGO:00430669.2CD40LG, IL2, PDCD1, RPS27A
8positive regulation of cell proliferationGO:00082849.1HTR2A, IL2, MECP2, STAT1
9tumor necrosis factor-mediated signaling pathwayGO:00332098.7CD40LG, RPS27A, STAT1, TNF

Molecular functions related to Progressive Multifocal Leukoencephalopathy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cytokine activityGO:00051259.8CD40LG, IL2, TNF
2tumor necrosis factor receptor bindingGO:00051649.3CD40LG, STAT1, TNF

Sources for Progressive Multifocal Leukoencephalopathy

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet